Comparing the current results to its competitors, Iterum Therapeutics Plc reported Revenue increase in the 3 quarter 2025 by 0 % year on year. The revenue growth was below Iterum Therapeutics Plc's competitors' average revenue growth of 8.96 %, achieved in the same quarter.
Iterum Therapeutics Plc, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 55.7 %
Iterum Therapeutics Plc's Comment on Competition and Industry Peers
The company operates in the pharmaceutical industry, which is marked by intense competition and rapid innovation. Its potential competitors include large pharmaceutical and biotechnology firms, specialty pharmaceutical companies, and generic drug manufacturers. Many competitors possess greater financial, technical, and human resources, along with more experience in product discovery, development, regulatory approvals, and commercialization. The company expects competition to intensify as new drugs are introduced and advanced technologies emerge. Additionally, new treatment methods for targeted diseases may affect the competitiveness or relevance of the company's product candidates.
April 29, 2024
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem: Bridging the Treatment Gap for uUTIsIterum Therapeutics, a leading pharmaceutical company, has recently resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Oral Sulopenem. This groundbreaking development marks the potential approval of the first oral penem in the United States, offering new hope for patients suffering from uncomplicated urinary tract infections (uUTIs). Additionally, it will be the second new oral treatment for uUTIs to be approved in over 25 years, if given the green light by regulatory authorities.Uncomplicated urinary tract infections are on...
March 6, 2024
Iterum Therapeutics Provides Business Update: Resubmission of NDA is On Track for First Half of Q2 24Iterum Therapeutics, a renowned pharmaceutical company specializing in the development and commercialization of innovative anti-infectives, recently released a press statement providing a comprehensive business update. Key among the updates is the resubmission of their New Drug Application (NDA), which remains firmly on track for the first half of the second quarter of 2024.The company has been diligently working towards resubmitting their NDA following the receipt of a Complete Response Letter (CRL) from the Food and Drug Administration (FDA) for their lead product candidate, sulopenem, in April 2021. The CR...
Ligand Pharmaceuticals Inc operates on a business model focused on discovering and acquiring new drugs and technologies to license them to pharmaceutical companies. They generate revenue through licensing fees, milestone payments, and royalties from the sales of their partnered products. Their approach allows them to leverage their expertise and resources while minimizing risk, ultimately leading to long-term value creation for their shareholders.
Innoviva Inc's business model revolves around the development and commercialization of pharmaceutical products. The company primarily focuses on creating strategic collaborations and partnerships with biopharmaceutical companies to advance innovative therapies. Innoviva generates revenue through royalty payments received based on the sales of its partnered products.
Sources:
Iterum Therapeutics Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Iterum Therapeutics Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
